Poxel

Merck Patent Gmbh

Poxel S.a.s.

Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

Universite Claude Bernard – Lyon1

Merck Sante

Ens-ecole Normale Superieure De Lyon

Edelris

Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gesellschaft

Lipha

Inserm

Daniel Cravo

Sophie Hallakou-Bozec

Didier Mesangeau

Gérard Moinet

Franck F Lepifre

Christine G Charon

Micheline R Kergoat

Liliane Doare

Franck Lepifre

Sébastien Bolze

Christine Charon

Sebastien Bolze

Patrice Andre

Didier Roche

Vincent Lotteau

Annick Audet

Jean-Denis Durand

Amaury Patin

Matthias Helmreich

Laurent Faveriel

Marine Gilardone

Pauline Radreau

Norbert Beier

Johannes Gleitz

Lars Thore Burgdorf

Gérard Coquerel

Samer Elbawab

Guillaume Levilain

G&eacute;rard Moinet

Pascale Fouqueray

Claus-Peter Niesert

Bernard Boudet

Sophie Hallakou-bozec

Saoussen Wacharine-Antar

Pascal Cardinael

Thierry Passemar

Xavier Leverve

Stéphanie Aubourg

The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.

Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection

Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection

The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, inflammation, cancer and cardiovascular diseases. 

Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof

Activators of AMPK and therapeutic uses thereof The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (NAFLD), non alcoholic steato-hepatitis (NASH), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies. 

Thienopyridone derivatives useful as activators of AMPK

The present invention relates to triazine derivatives of formula (I) for their use in the treatment of type 1 diabetes mellitus, and to compositions comprising said triazine derivatives. 

Treatment of type 1 diabetes

The invention relates to compounds of formula (I) wherein the radicals Rto Rhave the meaning according to claim, and/or physiologically acceptable salts thereof, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with the activity of AMP-activated protein kinase (AMPK). Another object of the invention concerns the use of said compounds for enhancing glucose homeostasis, improving podocytopathy and/or decreasing the production of reactive oxygen species (ROS). The invention also relates to a method for in-vitro diagnosing diabetic nephropathy and a method for screening compounds that reduce podocytopathy, in each case by applying synaptopodin as biomarker. 

Tetrahydrotriazine compounds for treating diseases associated with AMPK activity

The invention relates to a composition for use as a medicament comprising insulin in combination with at least one compound of formula (I) wherein the radicals Rto Rhave the meaning according to claim, and/or physiologically acceptable salts thereof. Another object of the invention concerns a pharmaceutical composition comprising as active ingredients effective amounts of insulin and at least one compound of formula (I), together with pharmaceutically tolerable adjuvants, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with insulin resistance. The invention also relates to a pharmaceutical package comprising insulin in a first dosage unit and at least one compound of formula (I) in a second dosage unit.

Combination of insulin with triazine derivatives and its use for treating diabetes

The invention relates to amino derivatives of dihydro-1,3,5-triazine, used for the treatment and/or prevention of diseases induced by ischemia and/or reperfusion, notably cardiac and renal complications.

Amino derivatives of dihydro-1,3,5-triazine used in the treatment of ischemia and/or reperfusion related diseases

The present invention relates to combinations of triazine derivatives and of insulin sensitizers.

Combination of triazine derivatives and insulin sensitisers

A new process for the enantiomeric separation of racemic 3,6-dihydro-1,3,5-triazine derivatives for the treatment of disorders associated with insulin-resistance syndrome, by preferential crystallization.

Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization

The present invention relates to a new process of separation of triazine derivatives enantiomers involving tartaric acid.

Separation of triazine derivatives enantiomers using tartaric acid

The present invention relates to compounds of formula (I) wherein X, Y, Z, R, R, Rare as defined in claim, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diabetes, metabolic syndrome, obesity, cancer, inflammation.

Quinoxalinedione derivatives useful as activators of AMPK-activated protein kinase

The present invention relates to compounds of formula (I) wherein R, Rand B, Bare as defined in claim, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diseases and disorders modulated by AMP agonists. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I). 

Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators

Combination of insulin with triazine derivatives

The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in claim, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diseases and disorders modulated by AMP agonists. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I). 

Growing community of inventors

Sartrouville, France

Daniel Cravo